Pilot Award –HT942526OCRPPA
- Pre-proposals due 13 July 2026
- Up to USD$350,000 over 2 years
- Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.
- Innovation is an important review criterion.
- Preliminary data allowed but not required as the goal is to develop preliminary data
- Clinical trials not allowed
- Encourages research aimed at extending the lives of advanced-state and recurrent patients is encouraged.
- Applications must address at least one of the Areas of Emphasis
- Apply here
- Document – Program Announcement – HT942526OCRPPA_GG
Clinical Trial Award – HT942526OCRPCTA
- Letters of Intent due 15 September 2026
- Up to USD$2.8M over 4 years
- Supports rapid implementation of clinical trials with the potential to significantly impact ovarian cancer.
- Projects may range from small proof-of-concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials in phase 0, 1, or 1/2.
- Preliminary data required
- Larger, more-definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population.
- Consumer advocate involvement required. Research team must include at least two or more ovarian cancer consumer advocates.
- Apply here
- Document – Program Announcement – HT942526OCRPCTA_GG
Investigator-Initiated Research Award – HT942526OCRPIIRA
- Pre-proposals due 13 July 2026
- up to USD$1.05M (Single PI) or USD$1.4M (Partnering PI Option) over 4 years
- Supports high-impact research that addresses a critical need and demonstrates the potential to make an important contribution to ovarian cancer or patient/survivor care.
- Preliminary data required
- Clinical trials not allowed
- Research on cell lines or animals allowed but must be justified
- Research aimed at extending the lives of advanced state and recurrent patients encouraged.
- Applications must address at least one of the Areas of Emphasis
- Apply here
- Document – Program Announcement – HT942526OCRPIIRA_GG
Ovarian Cancer Academy – Early-Career Investigator Award – HT942526OCRPOCCTAECI
- Letters of Intent due 15 September 2026
- Up to USD$1.125M over 4 years
- Supports the addition of new early-career investigators to the unique, interactive virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.
- Investigators must be within 5 years of their last postdoctoral research position or clinical fellowship or equivalent
- Requires a designated mentor who is an experienced ovarian cancer researcher with ovarian cancer funding. The mentor may be at a different institution
- Clinical trials not allowed
- Applications are encouraged from ECIs limited by lack of resources or other overwhelming obstacles, impacting their ability to commit to conducting ovarian cancer research.
- Applications must address at least one of the Areas of Emphasis
- Apply here
- Document – Program Announcement – HT942526OCRPOCAECI_GG
Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award – T942526OCRPOCCTAECI
- Letters of Intent due 15 September 2026
- Up to USD$1.4M over 4 years
- Supports the addition of new early-career investigators to the unique, interactive virtual Clinical Trial Academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.
- Investigators must be within 12 years of their last postdoctoral research position or clinical fellowship or equivalent
- Requires a designated mentor clinical trial experience and an active clinical trial. The mentor may be at a different institution
- Preliminary data required
- Clinical trials allowed
- Applications are encouraged from ECIs limited by lack of resources or other overwhelming obstacles, impacting their ability to commit to conducting ovarian cancer research.
- Applications must address at least one of the Areas of Emphasis
- Apply here
- Document – Program Announcement – HT942526OCRPOCCTAECI_GG
Areas of Emphasis
- Develop novel therapeutic strategies for treatment
- Identify and develop new strategies for risk stratification, screening, early-stage detection, accurate diagnosis and prognosis
- Identify and implement strategies to improve access to quality care, survivorship and quality of life
- Identify relationships between military service-related exposures and ovarian cancer
- Investigate innovative approaches for ovarian cancer prevention
- Provide access to quality care for military personnel, Veterans and their Families
- Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics and other critical events
